Funding Support and Author Disclosures Dr Neves has received consulting and speaking fees from AstraZeneca, BIAL, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and speaking fees from Merck. Dr Leite-Moreira has received research support from Boehringer Ingelheim, AstraZeneca, and Novartis. Dr Butler is a consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Bearing, CVRx, Cytokinetics, Edwards, Element Science, Faraday, Foundry, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Pfize, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll. Dr Zannad has received personal fees from Applied Therapeutics, Bayer, Betagenon, Biopeutics, Boehringer, BMS, CVRx, Cardior, Cereno Pharmaceutical, Cellprothera, Merck, Northsea, Novartis, NovoNordisk, Otsuka, and Owkin; has stock options at G3Pharmaceutical and equities at Cereno Pharmaceutical and Eshmoun Clinical Research; and is the founder of Cardiovascular Clinical Trialists (CVCT). Dr Packer has received personal fees for consulting from 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Medtronic, Moderna, Novartis, Pharmacocosmos, Reata, Regeneron, Roche, and Salamandra. Dr Ferreira has received research support from Boehringer Ingelheim, AstraZeneca, Novartis, Bayer, Salamandra, Bial, and Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.